Bristol Swallows Cost-Cutting Pill To Dull Pargluva Pain; Sales Force May Shrink

Bristol-Myers Squibb will undertake a cost-cutting program to offset the impact of the development delay of the investigational type 2 diabetes drug Pargluva.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet